Top Ten Articles 2018

Top Ten Articles on Atopic Dermatitis 2018: Chosen by the International Eczema Council.

1. Brunner, P. M., et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2017;141(6): 2094-2106.
   • Abstract
   • Link to Full Article
2. Guttman-Yassky, E., et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1): 155-172.
   • Abstract
   • Link to Full Article
3. Guttman-Yassky, E., et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4): 913-921.e919.
   • Abstract
   • Link to Full Article
4. Guttman-Yassky, E., et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5): 872-881.e876.
   • Abstract
   • Link to Article
5. Dyjack, N., et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype. J Allergy Clin Immunol. 2018;141(4): 1298-1309.
   • Abstract
   • Link to Article
6. Simpson, E. L., et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5): 863-871.e811.
   • Abstract
   • Link to Article
7. Kabashima, K., et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4): 1121-1130.e1127.
   • Abstract
   • Link to Article
8. Simpson, E. L., et al. Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. J Invest Dermatol. 2018;138(10): 2224-2233.
   • Abstract
   • Link to Article
9. Brunner, P. M., et al. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Ann Allergy Asthma Immunol. 2019;122(3): 318-330.e313.
   • Abstract
   • Link to Article
10. Glatz, M., et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS ONE. 2018;13(2): e0192443.
    • Abstract
    • Link to Article

Other Important Articles in AD: Chosen by the International Eczema Council.

1.  Werfel, T., et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol. 2018;S0091-6749(18)31578-1.
   • Abstract
   • Link to Article
2. Wollenberg, A., et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1): 135-141.
   • Abstract
   • Link to Article
3. Simpson, E. L., et al. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis. J Invest Dermatol. 2018;S0022-202X(18)32905-1.
   • Abstract
   • Link to Article
4. Brunner, P. M., et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol. 2019;143(1): 142-154.
   • Abstract
   • Link to Article
5. Thijs, J. L., et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. J Allergy Clin Immunol. 2018;141(4): 1523-1526.
   • Abstract
   • Link to Article
6. Altunbulakli, C., et al. Relations between epidermal barrier dysregulation and Staphylococcus species-dominated microbiome dysbiosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2018;142(5): 1643-1647.e1612.
   • Abstract
   • Link to Article
7. Sanyal, R. D., et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1): 99-110.e116.
   • Abstract
   • Link to Article
8. Simpson, E. L., et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4): 1013-1021.
   • Abstract
   • Link to Article
9. Myles, I. A., et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3(9).
   • Abstract
   • Link to Article
10. Blauvelt, A., et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(1): 158-167.e151.
    • Abstract
    • Link to Article
11. Taghavi Ardakani, A., et al. The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double-blinded, placebo-controlled trial. Pediatr Allergy Immunol. 2018;29(8): 834-840.
    • Abstract
    • Link to Article

Click on the ‘Abstract’ link for above-referenced articles on PubMed, along with copyright information.